Bone targeted therapies for bone metastasis in breast cancer

Journal of Clinical Medicine

Volumn 2, Issue 4, 2013, Pages 176-187

  Razaq, Wajeeha ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Bisphosphonates; Bone metastasis; Bone targeted therapy; Radiopharmaceuticals

Indexed keywords

ACTIVIN A; BALICATIB; BISPHOSPHONIC ACID DERIVATIVE; BOSUTINIB; CATHEPSIN K; CHEMOKINE RECEPTOR CXCR; CHEMOKINE RECEPTOR CXCR4; CTCE 9908; DASATINIB; DENOSUMAB; ENDOTHELIN 1; IMGN 388; INTEGRIN; L 000845704; MIV 711; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; ODANACATIB; ONO 5334; OSTEOCLAST DIFFERENTIATION FACTOR; PLERIXAFOR; RADIOPHARMACEUTICAL AGENT; SAMARIUM; SARACATINIB; STRONTIUM; TRABEDERSEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE DISEASE; BONE METASTASIS; BREAST CANCER; HUMAN; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; ONCOGENE SRC; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SKELETAL RELATED EVENT; WNT SIGNALING PATHWAY;

EID: 84983369702     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm2040176     Document Type: Review

References (54)

1. Meads, M.B.; Hazlehurst, L.A.; Dalton, W.S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin. Cancer Res. 2008, 14, 2519-2526.
2. Shiozawa, Y.; Havens, A.M.; Pienta, K.J.; Taichman, R.S. The bone marrow niche: Habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008, 22, 941-950.
3. Bellahcene, A.; Bachelier, R.; Detry, C.; Lidereau, R.; Clezardin, P.; Castronovo, V. Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Res. Treat. 2007, 101, 135-148.
4. Mundy, G.R. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2002, 2, 584-593.
5. Clézardin, P.; Teti, A. Bone metastasis: Pathogenesis and therapeutic implications. Clin. Exp. Metastasis 2007, 24, 599-608.
6. Leibbrandt, A.; Penninger, J.M. RANK/RANKL: Regulators of immune responses and bone physiology. Ann. N. Y. Acad. Sci. 2008, 1143, 123-150.
7. Leto, G. Activin A and bone metastasis. J. Cell. Physiol. 2010, 225, 302-309.
8. Stresing, V.; Daubiné, F.; Benzaid, I.; Mönkkönen, H.; Clézardin, P. Bisphosphonates in cancer therapy. Cancer Lett. 2007, 257, 16-35.
9. Mauri, D.; Valachis, A.; Polyzos, N.P.; Tsali, L.; Mavroudis, D.; Georgoulias, V.; Casazza, G. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. J. Natl. Compr. Cancer Netw. 2010, 8, 279-286.
10. Fizazi, K.; Lipton, A.; Mariette, X.; Body, J.-J.; Rahim, Y.; Gralow, J.R.; Gao, G.; Wu, L.; Sohn, W.; Jun, S. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J. Clin. Oncol. 2009, 27, 1564-1571.
11. Stopeck, A.; Boer, R.; Fujiwara, Y.; Lichinitser, M.; Tonkin, K.; Yardley, D.; Fan, M.; Jiang, Q.; Jun, S.; Dansey, R.; Braun, A. A comparison of denosumab versus zoledronic acid for the prevention of skeletal-related events in breast cancer patients with bone metastases. Cancer Res. 2009, 69, doi:10.1158/0008-5472.SABCS-09-22.
12. Whyte, M.P. The long and the short of bone therapy. N. Engl. J. Med. 2006, 354, 860-863.
13. Le Gall, C.; Bonnelye, E.; Clézardin, P. Cathepsin K inhibitors as treatment of bone metastasis. Curr. Opin. Support. Palliat. Care 2008, 2, 218-222.
14. Fuller, K.; Lawrence, K.M.; Ross, J.L.; Grabowska, U.B.; Shiroo, M.; Samuelsson, B.; Chambers, T.J. Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone 2008, 42, 200-211.
15. Yamashita, D.S.; Marquis, R.W.; Xie, R.; Nidamarthy, S.D.; Oh, H.-J.; Jeong, J.U.; Erhard, K.F.; Ward, K.W.; Roethke, T.J.; Smith, B.R.; et al. Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. J. Med. Chem. 2006, 49, 1597-1612.
16. Adami, S.; Supronik, J.; Hala, T.; Brown, J.P.; Garnero, P.; Haemmerle, S.; Ortmann, C.E.; Bouisset, F.; Trechsel, U. Effect of 1 year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis. J. Bone Miner. Res. 2006, 21, 1085.
17. Peroni, A.; Zini, A.; Braga, V.; Colato, C.; Adami, S.; Girolomoni, G. Drug-induced morphea: Report of a case induced by balicatib and review of the literature. J. Am. Acad. Dermatol. 2008, 59, 125-129.
18. Rucci, N.; Recchia, I.; Angelucci, A.; Alamanou, M.; Del Fattore, A.; Fortunati, D.; Susa, M.; Fabbro, D.; Bologna, M.; Teti, A. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: Implications for therapy. J. Pharmacol. Exp. Ther. 2006, 318, 161-172.
19. Hiscox, S.; Jordan, N.J.; Morgan, L.; Green, T.P.; Nicholson, R.I. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin. Exp. Metastasis 2007, 24, 157-167.
20. Hiscox, S.; Morgan, L.; Green, T.P.; Barrow, D.; Gee, J.; Nicholson, R.I. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res. Treat. 2006, 97, 263-274.
21. Verbeek, B.S.; Vroom, T.M.; Adriaansen-Slot, S.S.; Ottenhoff-Kalff, A.E.; Geertzema, J.G.; Hennipman, A.; Rijksen, G. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J. Pathol. 1996, 180, 383-388.
22. Metcalf, C.A., III; van Schravendijk, M.R.; Dalgarno, D.C.; Sawyer, T.K. Targeting protein kinases for bone disease: Discovery and development of Src inhibitors. Curr. Pharm. Des. 2002, 8, 2049-2075.
23. Marzia, M.; Sims, N.A.; Voit, S.; Migliaccio, S.; Taranta, A.; Bernardini, S.; Faraggiana, T.; Yoneda, T.; Mundy, G.R.; Teti, A. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J. Cell Biol. 2000, 151, 311-320.
24. Soriano, P.; Montgomery, C.; Geske, R.; Bradley, A. Targeted disruption of the c-Src proto-oncogene leads to osteopetrosis in mice. Cell 1991, 64, 693-702.
25. Zhang, X.H.; Wang, Q.; Gerald, W.; Hudis, C.A.; Norton, L.; Smid, M.; Foekens, J.A.; Massagué, J. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009, 16, 67-78.
26. Hall, T.J.; Schaeublin, M.; Missbach, M. Evidence that c-Src is involved in the process of osteoclastic bone resorption. Biochem. Biophys. Res. Commun. 1994, 199, 1237-1244.
27. Lombardo, L.J.; Lee, F.Y.; Chen, P.; Norris, D.; Barrish, J.C.; Behnia, K.; Castaneda, S.; Cornelius, L.A.; Das, J.; Doweyko, A.M. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 2004, 47, 6658-6661.
28. Finn, R.S.; Finn, R.S.; Bengala, C.; Ibrahim, N.; Strauss, L.C.; Fairchild, J.; Sy, O.; Roche, H.; Sparano, J.; Goldstein, L.J. Phase II trial of dasatinib in triple-negative breast cancer: Results of study CA180059. Cancer Res. 2009, 69, doi:10.1158/0008-5472.SABCS-3118.
29. Baselga, J.; Cervantes, A.; Martinelli, E.; Chirivella, I.; Hoekman, K.; Hurwitz, H.I.; Jodrell, D.I.; Hamberg, P.; Casado, E.; Elvin, P.; et al. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin. Cancer Res. 2010, 16, 4876-4883.
30. Jallal, H.; Valentino, M.L.; Chen, G.; Boschelli, F.; Ali, S.; Rabbani, S.A. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res. 2007, 67, 1580-1588.
31. Zou, W.; Kitaura, H.; Reeve, J.; Long, F.; Tybulewicz, V.L.J.; Shattil, S.J.; Ginsberg, M.H.; Ross, F.P.; Teitelbaum, S.L. Syk, c-Src, the avb3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J. Cell Biol. 2007, 176, 877-888.
32. Clézardin, P. Integrins in bone metastasis formation and potential therapeutic implications. Curr. Cancer Drug Targets 2009, 9, 801-806.
33. Desgrosellier, J.S.; Cheresh, D.A. Integrins in cancer: Biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10, 9-22.
34. Müller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M.E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S.N.; et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410, 50-56.
35. Cabioglu, N.; Sahin, A.A.; Morandi, P.; Meric-Bernstam, F.; Islam, R.; Lin, H.Y.; Bucana, C.D.; Gonzalez-Angulo, A.M.; Hortobagyi, G.N.; Cristofanilli, M. Chemokine receptors in advanced breast cancer: Differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann. Oncol. 2009, 20, 1013-1019.
36. Richert, M.M.; Vaidya, K.S.; Mills, C.N.; Wong, D.; Korz, W.; Hurst, D.R.; Welch, D.R. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol. Rep. 2009, 21, 761-767.
37. Wong, D.; Korz, W. Translating an antagonist of chemokine receptor CXCR4: From bench to bedside. Clin. Cancer Res. 2008, 14, 7975-7980.
38. Hotte, S.J.; Hirte, H.W.; Iacobucci, A. Final Results of a Phase I/II Study of CTCE-9908, a Novel Anticancer Agent that Inhibits CXCR4, in Patients with Advanced Solid Cancers. In Proceedings of the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, 21-24 October 2008.
39. Brave, M.; Farrell, A.; Ching Lin, S.; Ocheltree, T.; Pope Miksinski, S.; Lee, S.L. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology 2010, 78, 282-288.
40. Juárez, P.; Guise, T.A. TGFb pathway as a therapeutic target in bone metastases. Curr. Pharm. Des. 2010, 16, 1301-1312.
41. Oettle, H.; Hilbig, A.; Seufferlein, T.; Schmid, R.M.; Luger, T.; von Wichert, G.; Schmaus, S.; Heinrichs, H.; Schlingensiepen, K. Interim results of the phase I/II study of trabedersen (AP 12009) in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma. J. Clin. Oncol. 2009, 27, 4619.
42. Bogdahn, U.; Schneider, T.; Oliushine, V.; Parfenov, V.; Mahapatra, A.K.; Balasubramaniam, A.; Venkataramana, N.; Stockhammer, G.; Heinrichs, H.; Schlingensiepen, K.; Trabedersen Glioma Study Group. Randomized, active-controlled phase IIb study with trabedersen (AP 12009) in recurrent or refractory high-grade glioma patients: Basis for phase III endpoints. J. Clin. Oncol. 2009, 27, 2037.
43. Padua, D.; Zhang, X.H.-F.; Wang, Q.; Nadal, C.; Gerald, W.L.; Gomis, R.R.; Massagué, J. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008, 133, 66-77.
44. Choi, Y.; Arron, J.R.; Townsend, M.J. Promising bone-related therapeutic targets for rheumatoid arthritis. Nat. Rev. Rheumatol. 2009, 5, 543-548.
45. Tian, E.; Zhan, F.; Walker, R.; Rasmussen, E.; Ma, Y.; Barlogie, B.; Shaughnessy, J.D., Jr. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 2003, 349, 2483-2494.
46. Yaccoby, S.; Ling, W.; Zhan, F.; Walker, R.; Barlogie, B.; Shaughnessy, J.D., Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007, 109, 2106-2111.
47. Fulciniti, M.; Tassone, P.; Hideshima, T.; Vallet, S.; Nanjappa, P.; Ettenberg, S.A.; Shen, Z.; Patel, N.; Tai, Y.T.; Chauhan, D.; et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009, 114, 371-379.
48. Bu, G.; Lu, W.; Liu, C.C.; Selander, K.; Yoneda, T.; Hall, C.; Keller, E.T.; Li, Y. Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: Implication for breast cancer osteolytic bone metastases. Int. J. Cancer 2008, 123, 1034-1042.
49. Leto, G.; Incorvaia, L.; Badalamenti, G.; Tumminello, F.M.; Gebbia, N.; Flandina, C.; Crescimanno, M.; Rini, G. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin. Exp. Metastasis 2006, 23, 117-122.
50. Nelson, J.; Bagnato, A.; Battistini, B.; Nisen, P. The endothelin axis: Emerging role in cancer. Nat. Rev. Cancer 2003, 3, 110-116.
51. Grimshaw, M.J.; Hagemann, T.; Ayhan, A.; Gillett, C.E.; Binder, C.; Balkwill, F.R. A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res. 2004, 64, 2461-2468.
52. Janjan, N.A. Radiation for bone metastases: Conventional techniques and the role of systemic radiopharmaceuticals. Cancer 1997, 80, 1628-1645.
53. Lewington, V.J.; McEwan, A.J.; Ackery, D.M.; Bayly, R.J.; Keeling, D.H.; Macleod, P.M.; Porter, A.T.; Zivanovic, M.A. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur. J. Cancer 1991, 27, 954-958.
54. Resche, I.; Chatal, J.-F.; Pecking, A.; Eli, P.; Duchesne, G.; Rubens, R.; Fogelman, I.; Houston, S.; Fauser, A.; Fischer, M.; Wilkins, D. A dose-controlled study of 153Sm-Ethylenedia minetetramethylenephosphate (EDTMP) in the treatment of patients with painful bone metastases. Eur. J. Cancer 1997, 33, 1583-1591.